Cardiol Therapeutics | Finanzwire

Basculer en Français

10280	Companies
212875	Keywords
142663	Articles
112723	Press releases

Home
Companies
Cardiol Therapeutics

BRIEF

published on 04/17/2026 at 15:36, 8 days 11 hours ago

Research Update on Cardiol Therapeutics by First Berlin Equity Research

Clinical Trials Research Update Price Target Cardiol Therapeutics Capital Raise
PRESS RELEASE

published on 04/17/2026 at 15:31, 8 days 11 hours ago

Original-Research: Cardiol Therapeutics Inc (von First Berlin Equity Research GmbH): BUY
First Berlin Equity Research updates BUY recommendation for Cardiol Therapeutics Inc to USD 7.50 target price due to recent corporate updates and pipeline progress, including MAVERIC trial advancements

Cardiol Therapeutics Inc First Berlin Equity Research Buy Recommendation Pipeline Progress MAVERIC Trial
BRIEF

published on 12/17/2025 at 14:43, 4 months 8 days ago

First Berlin Equity Research Updates Cardiol Therapeutics to "Buy" with a Lowered Target Price

Buy Recommendation Target Price Adjustment Cardiol Therapeutics Phase II ARCHER Study Myocarditis
PRESS RELEASE

published on 12/17/2025 at 14:38, 4 months 8 days ago

Original-Research: Cardiol Therapeutics Inc (von First Berlin Equity Research GmbH): BUY
First Berlin Equity Research updates BUY recommendation for Cardiol Therapeutics Inc., lowering price target to USD 7.80 based on positive Phase II ARCHER data on CardiolRx for acute myocarditis

First Berlin Equity Research Buy Recommendation Acute Myocarditis Cardiol Therapeutics Inc. Phase II ARCHER Data
BRIEF

published on 10/23/2025 at 12:56, 6 months 2 days ago

Cardiol Therapeutics Secures Funding with USD 11.4 Million Private Placement

Private Placement Clinical Trials Financial Outlook Cardiol Therapeutics Heart-Failure Therapy
PRESS RELEASE

published on 10/23/2025 at 12:51, 6 months 2 days ago

Original-Research: Cardiol Therapeutics Inc (von First Berlin Equity Research GmbH): BUY
First Berlin Equity Research updates Cardiol Therapeutics Inc with a BUY rating and USD 8.50 price target. The private placement secures funds for pivotal trials and new product development

Private Placement Cardiol Therapeutics Inc First Berlin Equity Research BUY Rating USD 8.50 Price Target
BRIEF

published on 08/12/2025 at 13:36, 8 months 13 days ago

Cardiol Therapeutics: Phase II Trial Results and Positive Stock Outlook

BUY Rating Cardiol Therapeutics CardiolRx Phase II ARCHER Trial Acute Myocarditis
PRESS RELEASE

published on 08/12/2025 at 13:31, 8 months 13 days ago

Original-Research: Cardiol Therapeutics Inc (von First Berlin Equity Research GmbH): BUY
First Berlin Equity Research updates BUY recommendation for Cardiol Therapeutics Inc after positive phase II trial results for CardiolRx in acute myocarditis

Cardiol Therapeutics Inc First Berlin Equity Research Phase II Trial CardiolRx Acute Myocarditis
BRIEF

published on 04/23/2025 at 15:29, 1 year ago

Cardiol Therapeutics Advances in Pivotal Phase III Study

FDA Approval Cardiol Therapeutics Phase III Study Recurrent Pericarditis CardiolRxT
PRESS RELEASE

published on 04/23/2025 at 15:24, 1 year ago

Original-Research: Cardiol Therapeutics Inc (von First Berlin Equity Research GmbH): Buy
First Berlin Equity Research updates recommendation for Cardiol Therapeutics Inc, maintaining Buy rating and USD 8.50 target price. CardiolRxT phase III study enrollment for recurrent pericarditis (RP) shows promise for FDA approval

FDA Approval Cardiol Therapeutics Inc First Berlin Equity Research BUY Rating CardiolRxT

Accesswire

Published on 04/25/2026 at 03:10, 23 hours 57 minutes ago

BEACN Announces Financial Results for Year Ended December 31, 2025
Published on 04/24/2026 at 22:05, 1 day 5 hours ago

Critical Elements Mourns the Loss of Director Marc Simpson
Published on 04/24/2026 at 22:00, 1 day 5 hours ago

Kidoz Inc. to Present 2025 Results and Highlight Platform Expansion and Business Momentum
Published on 04/24/2026 at 15:00, 1 day 12 hours ago

Norsemont Reports Significant Copper, Lead & Zinc Values in Three Choquelimpie Drill Holes
Published on 04/24/2026 at 15:00, 1 day 12 hours ago

First Canadian Graphite Appoints Scott Kelly As Chief Financial Officer

View all ACCESSWIRE

EQS Group

Published on 04/25/2026 at 16:25, 10 hours 42 minutes ago

Leading a New Era of Family Mobility! CHERY TIGGO V, the 3-in-1 Family Vehicle, Debuts at AutoChina2026
Published on 04/24/2026 at 22:43, 1 day 4 hours ago

EQS-Adhoc: Marley Spoon Group SE: Closing of the financing transaction in connection with the financial restructuring of its German subsidiary Marley Spoon SE with increased financing amou
Published on 04/24/2026 at 22:05, 1 day 5 hours ago

Berlin Heals Presents Positive Late Breaking Results from the CMIC-III First-In-Human Less Invasive Study
Published on 04/24/2026 at 18:12, 1 day 8 hours ago

EQS-Adhoc: clearvise AG reviews dividend proposal in line with its dividend strategy and postpones Annual General Meeting
Published on 04/24/2026 at 18:07, 1 day 9 hours ago

DEAG sets new records for revenue and earnings in financial year 2025 – excellently positioned for long-term growth

Les Echos

Published on 04/24/2026 at 17:45, 1 day 9 hours ago

Share buyback for cancellation
Published on 04/24/2026 at 17:45, 1 day 9 hours ago

Imerys-04-2026-information-share-capital-and-voting-rights-as-of-31-March-2026
Published on 04/24/2026 at 16:37, 1 day 10 hours ago

Availability of the 2025 Universal Registration Document (URD)
Published on 04/23/2026 at 19:27, 2 days 7 hours ago

Annual Shareholders' Meeting 2026 - Conditions of availability of the preparatory documents
Published on 04/23/2026 at 18:18, 2 days 8 hours ago

Aéroports de Paris SA - Sale by Groupe ADP of securities representing 3.4% with option to sell an additional 3.9% of GAL's equity share capital to GMR Group

View all LES ECHOS COMFI WIRE